S. Gill, C. Loprinzi, D. Sargent, S. Thomé, S. Alberts et al., Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?, Journal of Clinical Oncology, vol.22, issue.10, pp.1797-1806, 2004.
DOI : 10.1200/JCO.2004.09.059

R. Gray, J. Barnwell, C. Mcconkey, R. Hills, N. Williams et al., Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study, Lancet, vol.370, pp.2020-2029, 2007.

T. André, C. Boni, L. Mounedji-boudiaf, M. Navarro, J. Tabernero et al., Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer, New England Journal of Medicine, vol.350, issue.23, pp.2343-2351, 2004.
DOI : 10.1056/NEJMoa032709

P. Flynn, American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer, J Clin Oncol, vol.22, pp.3408-3419, 2004.

R. Labianca, B. Nordlinger, G. Beretta, S. Mosconi, M. Mandalà et al., ESMO Guidelines Working Group. Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.24, issue.6, pp.64-72, 2013.

C. Guastadisegni, M. Colafranceschi, L. Ottini, and E. Dogliotti, Microsatellite instability as a marker of prognosis and response to therapy: A meta-analysis of colorectal cancer survival data, European Journal of Cancer, vol.46, issue.15, pp.2788-2798, 2010.
DOI : 10.1016/j.ejca.2010.05.009

D. Sargent, S. Marsoni, G. Monges, S. Thibodeau, R. Labianca et al., Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer, Journal of Clinical Oncology, vol.28, issue.20, pp.3219-3226, 2010.
DOI : 10.1200/JCO.2009.27.1825

A. Zaanan, P. Cuilliere-dartigues, A. Guilloux, Y. Parc, C. Louvet et al., Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin, Annals of Oncology, vol.21, issue.4, pp.772-780, 2010.
DOI : 10.1093/annonc/mdp383

D. 12-tougeron, G. Mouillet, I. Trouilloud, T. Lecomte, R. Coriat et al., Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study, Journal of the National Cancer Institute, vol.108, issue.7, p.438, 2016.
DOI : 10.1093/jnci/djv438

N. Suraweera, A. Duval, M. Reperant, C. Vaury, D. Furlan et al., Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR, Gastroenterology, vol.123, issue.6, pp.1804-1811, 2002.
DOI : 10.1053/gast.2002.37070

H. Quah, J. Chou, M. Gonen, J. Shia, D. Schrag et al., Identification of Patients with High-Risk Stage II Colon Cancer for Adjuvant Therapy, Diseases of the Colon & Rectum, vol.51, issue.5, pp.503-507, 2008.
DOI : 10.1007/s10350-008-9246-z

M. Morris, C. Platell, B. De-boer, K. Mccaul, and B. Iacopetta, Population-based study of prognostic factors in stage II colonic cancer, British Journal of Surgery, vol.24, issue.7, pp.866-871, 2006.
DOI : 10.1002/bjs.5345

G. Burdy, Y. Panis, A. Alves, J. Nemeth, A. Lavergne-slove et al., Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence, Diseases of the Colon & Rectum, vol.44, issue.11, pp.1682-1688, 2001.
DOI : 10.1007/BF02234390

K. Kotake, S. Honjo, K. Sugihara, Y. Hashiguchi, T. Kato et al., Number of Lymph Nodes Retrieved is an Important Determinant of Survival of Patients with Stage II and Stage III Colorectal Cancer, Japanese Journal of Clinical Oncology, vol.42, issue.1, pp.29-35, 2012.
DOI : 10.1093/jjco/hyr164

R. Swanson, C. Compton, A. Stewart, and K. Bland, The Prognosis of T3N0 Colon Cancer Is Dependent on the Number of Lymph Nodes Examined, Annals of Surgical Oncology, vol.122, issue.1, pp.65-71, 2003.
DOI : 10.1245/ASO.2003.03.058

L. Voyer, T. Sigurdson, E. Hanlon, A. Mayer, R. Macdonald et al., Colon Cancer Survival Is Associated With Increasing Number of Lymph Nodes Analyzed: A Secondary Survey of Intergroup Trial INT-0089, Journal of Clinical Oncology, vol.21, issue.15, pp.2912-2919, 2003.
DOI : 10.1200/JCO.2003.05.062

F. Pagès, A. Berger, M. Camus, F. Sanchez-cabo, A. Costes et al., Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer, New England Journal of Medicine, vol.353, issue.25, pp.2654-2666, 2005.
DOI : 10.1056/NEJMoa051424

J. Galon, A. Costes, F. Sanchez-cabo, A. Kirilovsky, B. Mlecnik et al., Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome, Science, vol.313, issue.5795, pp.1960-1964, 2006.
DOI : 10.1126/science.1129139

F. Pagès, A. Kirilovsky, B. Mlecnik, M. Asslaber, M. Tosolini et al., In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer, Journal of Clinical Oncology, vol.27, issue.35, pp.5944-5951, 2009.
DOI : 10.1200/JCO.2008.19.6147

D. Klingbiel, Z. Saridaki, A. Roth, F. Bosman, M. Delorenzi et al., Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial, Annals of Oncology, vol.26, issue.1, pp.126-132, 2015.
DOI : 10.1093/annonc/mdu499

K. Søreide, B. Nedrebø, J. Søreide, A. Slewa, and H. Kørner, Lymph Node Harvest in Colon Cancer: Influence of Microsatellite Instability and Proximal Tumor Location, World Journal of Surgery, vol.208, issue.12, pp.2695-2703, 2009.
DOI : 10.1007/s00268-009-0255-4

H. Trivedi, U. Chamarthy, L. Dicarlo, J. Herman, and G. Srkalovic, Prognostic factors of overall survival for patients with stage II colon cancer, Acta Medica Academica, vol.43, issue.2, pp.134-143, 2014.
DOI : 10.5644/ama2006-124.112

E. Belt, E. Te-velde, O. Krijgsman, R. Brosens, M. Tijssen et al., High Lymph Node Yield is Related to Microsatellite Instability in Colon Cancer, Annals of Surgical Oncology, vol.53, issue.4, pp.1222-1230, 2012.
DOI : 10.1245/s10434-011-2091-7

S. Hatano, H. Ishida, K. Ishibashi, K. Kumamoto, N. Haga et al., Identification of Risk Factors for Recurrence in High-Risk Stage II Colon Cancer, International Surgery, vol.98, issue.2, pp.114-121, 2013.
DOI : 10.9738/CC131

R. Gertler, R. Rosenberg, T. Schuster, and H. Friess, Defining a high-risk subgroup with colon cancer stages I and II for possible adjuvant therapy, European Journal of Cancer, vol.45, issue.17, pp.2992-2999, 2009.
DOI : 10.1016/j.ejca.2009.07.008

C. Liebig, G. Ayala, J. Wilks, G. Verstovsek, H. Liu et al., Perineural Invasion Is an Independent Predictor of Outcome in Colorectal Cancer, Journal of Clinical Oncology, vol.27, issue.31, pp.5131-5137, 2009.
DOI : 10.1200/JCO.2009.22.4949

R. Kennedy, M. Bylesjo, P. Kerr, T. Davison, J. Black et al., Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue, Journal of Clinical Oncology, vol.29, issue.35, pp.4620-4626, 2011.
DOI : 10.1200/JCO.2011.35.4498

A. Venook, D. Niedzwiecki, M. Lopatin, X. Ye, M. Lee et al., Biologic Determinants of Tumor Recurrence in Stage II Colon Cancer: Validation Study of the 12-Gene Recurrence Score in Cancer and Leukemia Group B (CALGB) 9581, Journal of Clinical Oncology, vol.31, issue.14, pp.1775-1781, 2013.
DOI : 10.1200/JCO.2012.45.1096

K. Malinowsky, U. Nitsche, K. Janssen, F. Bader, C. Späth et al., Activation of the PI3K/AKT pathway correlates with prognosis in stage II colon cancer, British Journal of Cancer, vol.785, issue.8, pp.2081-2089, 2014.
DOI : 10.1038/bjc.2011.504

M. Merok, T. Ahlquist, E. Røyrvik, K. Tufteland, M. Hektoen et al., Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series, Annals of Oncology, vol.24, issue.5, pp.1274-1282, 2013.
DOI : 10.1093/annonc/mds614

U. Shin, S. Cho, S. Moon, S. Park, S. Jee et al., Is Microsatellite Instability Really a Good Prognostic Factor of Colorectal Cancer?, Annals of Coloproctology, vol.30, issue.1, pp.28-34, 2014.
DOI : 10.3393/ac.2014.30.1.28

Z. Saridaki, J. Souglakos, and V. Georgoulias, Prognostic and predictive significance of MSI in stages II/III colon cancer, World Journal of Gastroenterology, vol.20, issue.22, pp.6809-6814, 2014.
DOI : 10.3748/wjg.v20.i22.6809

H. Blons, J. Emile, L. Malicot, K. Julié, C. Zaanan et al., Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset, Annals of Oncology, vol.25, issue.12, pp.2378-2385, 2014.
DOI : 10.1093/annonc/mdu464

J. Taieb, A. Zaanan, K. Le-malicot, C. Julie, H. Blons et al., Prognostic Effect of BRAF and KRAS mutations in patients with stage III colon cancer treated with leucovorin, fluorouracil, and oxaliplatin with or without cetuximab: a post hoc analysis of the PETACC-8 trial, JAMA Oncol, vol.14, pp.1-11, 2016.

R. Kelley and A. Venook, Prognostic and Predictive Markers in Stage II Colon Cancer: Is There a Role for Gene Expression Profiling?, Clinical Colorectal Cancer, vol.10, issue.2, pp.73-80, 2011.
DOI : 10.1016/j.clcc.2011.03.001

G. 39-yothers, O. Connell, M. Lee, M. Lopatin, M. Clark-langone et al., Validation of the 12-Gene Colon Cancer Recurrence Score in NSABP C-07 As a Predictor of Recurrence in Patients With Stage II and III Colon Cancer Treated With Fluorouracil and Leucovorin (FU/LV) and FU/LV Plus Oxaliplatin, Journal of Clinical Oncology, vol.31, issue.36, pp.4512-4519, 2013.
DOI : 10.1200/JCO.2012.47.3116

P. Dalerba, D. Sahoo, S. Paik, X. Guo, G. Yothers et al., CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer, New England Journal of Medicine, vol.374, issue.3, pp.211-222, 2016.
DOI : 10.1056/NEJMoa1506597